drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous gene-engineered T cells modified ex vivo to express a chimeric antigen receptor targeting CD147, enabling antigen-specific activation and cytotoxic killing of CD147-positive malignant T cells in relapsed/refractory T-cell non-Hodgkin’s lymphoma; administered in a dose-escalation range of 0.1–2.0×10^6 CAR T cells/kg.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered ex vivo to express a chimeric antigen receptor targeting CD147; CAR binding to CD147 activates T cells via CD3ζ and costimulatory signaling, driving antigen-specific cytotoxic killing of CD147-positive malignant T cells.
drug_name
CD147-CAR T cells
nct_id_drug_ref
NCT05013372